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Abstract
Addiction is a chronic brain disorder that progressively invades all aspects of personal life. 
Accordingly, addiction to opiates severely impairs interpersonal relationships, and the resulting 
social isolation strongly contributes to the severity and chronicity of the disease. Uncovering new 
therapeutic strategies that address this aspect of addiction is therefore of great clinical relevance. 
We recently established a mouse model of heroin addiction in which, following chronic heroin 
exposure, ‘abstinent’ mice progressively develop a strong and long-lasting social avoidance 
phenotype. Here, we explored and compared the efficacy of two pharmacological interventions in 
this mouse model. Because clinical studies indicate some efficacy of antidepressants on emotional 
dysfunction associated with addiction, we first used a chronic 4-week treatment with the 
serotonergic antidepressant fluoxetine, as a reference. In addition, considering prodepressant 
effects recently associated with kappa opioid receptor signaling, we also investigated the kappa 
opioid receptor antagonist norbinaltorphimine (norBNI). Finally, we assessed whether fluoxetine 
and norBNI could reverse abstinence-induced social avoidance after it has established. Altogether, 
our results show that two interspaced norBNI administrations are sufficient both to prevent and to 
reverse social impairment in heroin abstinent animals. Therefore, kappa opioid receptor 
antagonism may represent a useful approach to alleviate social dysfunction in addicted individuals.
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INTRODUCTION
Addiction is a chronic brain disorder with devastating consequences for individuals and their 
social life (Volkow, Baler & Goldstein 2011; Everitt 2014). Natural history of the disease has 
been classically conceptualized as a vicious cycle. Drug intoxications initially produce 
positive subjective effects but are followed by aversive signs of withdrawal when 
pharmacological drug effects unfold. In turn, withdrawal feeds into a ‘preoccupation’ stage, 
where drug craving irresistibly drives drug-seeking behaviors and precipitates relapse (Koob 
& Volkow 2010). Escaping this vicious cycle and maintaining abstinence is a lifelong 
challenge for addicted individuals.
Several causes contribute to interrupt drug abstinence. External factors, such as stressful life 
experiences and drug-associated environments (Koob & Volkow 2010), are well-studied 
determinants for relapse. Alteration of emotional homeostasis during the course of the 
disease represents yet another key factor, which is less understood. Abstinence, notably from 
opiate abuse, is characterized by a symptomatology encompassing anxiety and depressive 
disorders, as well as social isolation (Grella et al. 2009). Emotional and social dysfunction in 
addicted subjects is a major concern that associates with a more severe and longer clinical 
course, as well as higher relapse rates during abstinence periods (Bakken, Landheim & 
Vaglum 2007). Several rodent paradigms have been used to study the various facets of 
emotional deficits associating with opiate abuse. In summary, chronic opiate exposure was 
found to potentiate stress vulnerability (Blatchford et al. 2005), defensive behaviors (Harris 
& Aston-Jones 1993, 2001) and depressive-like behaviors (Grasing & Ghosh 1998; Anraku 
et al. 2001; Hodgson et al. 2009; Jia et al. 2013). Recently, we established a novel mouse 
model of drug abstinence focused on social behaviors. We showed that abstinence from both 
morphine and heroin, two prototypical opiates, progressively leads over the course of 4 
weeks to the emergence of a long-lasting, low sociability phenotype (corresponding to both 
decreased interactions and increased grooming when encountering a new congener), which 
also associates with depressive-like features (Goeldner et al. 2011; Lutz & Kieffer 2013; 
Lutz et al. 2014).
Rigorous clinical studies have been conducted to evaluate classical antidepressants in the 
context of emotional comorbidities of addiction (Nunes & Levin 2006). These studies 
reported mixed results, some positive but some negative, emphasizing the need to investigate 
other therapeutic options. Over the last few years, animal studies have identified the kappa 
opioid receptor (KOR) as a promising target for innovative antidepressant strategies 
(Bruchas, Land & Chavkin 2010; Knoll & Carlezon 2010; Lalanne et al. 2014), prompting 
clinicians to assess the potential of targeting this particular opioid receptor to treat emotional 
symptoms in drug abuse. Buprenorphine, for example, is a complex opiate drug that 
activates the mu opioid receptor (MOR), the main molecular mediator of reinforcing 
properties of opiates, but is also an antagonist at the KOR. Considering the treatment of 
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addiction, buprenorphine was used primarily as a substitution to illegal opiates because of its 
MOR activity; interestingly, some authors reported beneficial effects on emotional distress 
(Gerra et al. 2004) possibly because of KOR blockade. Recent studies have also investigated 
combined administration of buprenorphine and MOR antagonists, in order to achieve KOR 
blockade while limiting the risk of abuse associated with MOR activation. Results have 
revealed significant improvement of depressive symptoms (Ehrich et al. 2014; Almatroudi et 
al. 2015), further reinforcing the possibility that KOR antagonism may have intrinsic 
antidepressant potential.
Because MOR and KOR exert complex and distinct controls over emotions and sociability, 
animal studies and clinical trials that target both receptor types may be difficult to interpret. 
Also, systemic KOR-targeting therapies have not been investigated in animal models of 
social comorbidities of opiate addiction. In the present study, we hypothesized that KOR 
signaling may play a role in the emergence of low sociability in opiate addicts and evaluated 
the efficacy of a pure KOR antagonist in a validated mouse model of social deficits in heroin 
abstinence. We examined the ability of norBNI to prevent low sociability in heroin abstinent 
mice and to reverse this phenotype after it has been established, using the antidepressant 
fluoxetine (FLX) as a comparison. Our results indicate that these two pharmacological 
interventions had protective effects during heroin abstinence, in prevention and reversion 
experiments, against both low social interactions and increased grooming.
METHODS
Animals
Male C57BL/6JCrl mice (Charles Rivers Laboratories, St.-Germain-sur-l’Arbresle, France) 
were habituated to housing conditions during 2 weeks and were 10-week old at the 
beginning of chronic heroin exposure. Animals were housed four/cage and maintained under 
standard laboratory conditions (12-hour light–dark cycle with lights on at 7 AM; food and 
water available ad libitum). All experimental procedures were performed according to 
standard ethical guidelines (European Union Council Directive of 22 September 2010, 
directive 2010/63/UE and IGBMC-ICS ethical comity, Com’Eth).
Heroin treatment
Heroin (Francopia, Gentilly, France) was administered intraperitoneally (i.p.) twice daily (8 
AM and 6 PM) with escalating doses (10, 20, 30, 40, 50 mg/kg for 5 days, followed by a 
single 50 mg/kg injection on day 6) or saline solution as a control. We previously showed 
that this regimen induces a strong physical dependence, one of the hallmarks of opiate 
addiction in human (Lutz et al. 2014). Compared with our previous studies on morphine 
abstinence (20–100 mg/kg morphine doses) and based on systematic analyses of opiate-
induced physical dependence across inbred mouse strains (Kest et al. 2002; Klein et al. 
2008), we selected heroin doses divided by a factor of two (10–50 mg/kg). Although the 
signs of withdrawal qualitatively differ (refer to Lutz et al. 2014), the global scores for acute 
naloxone-precipitated withdrawal are comparable across these two morphine and heroin 
regimens. To avoid reciprocal social influences between saline- and heroin-treated mice 
(Cole et al. 2012), housing cages contained only saline-treated or only opiate-treated mice. 
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Following the 6-day heroin regimen, animals experienced spontaneous withdrawal in their 
home cages and were maintained drug free (i.e. ‘abstinent’) for 4 or 8 weeks in prevention or 
reversion experiments, respectively.
Fluoxetine treatment
The 10 mg/kg FLX dose was chosen based on our previous studies (Goeldner et al. 2011; 
Lutz et al. 2014). Briefly, the amount of FLX (Sigma-Aldrich, Lyon, France) supplemented 
to regular chow was based upon initial body weight of animals and daily average food 
intake: A 30 g mouse consuming 4 g/day (dry weight) of chow supplemented with 0.3 mg 
FLX received an approximate 10 mg/kg/24 hour dose. The 10 mg/kg was chosen as, in pilot 
experiments (refer to supplementary online material in Goeldner et al. 2011), it did not alter 
food intake during the 3 weeks of treatment and was ineffective on despair-related behaviors 
in naïve mice. In contrast, a higher (30 mg/kg) FLX dose was rejected as it severely reduced 
food intake and produced signs of serotonergic overdosage in some animals.
Norbinaltorphimine treatment
Norbinaltorphimine (norBNI) (Tocris Bioscience, Lille, France) is a long-acting antagonist 
with a greater than 100-fold selectivity for KOR over other opioid receptors (Metcalf & 
Coop 2005). Two injections of norBNI were administered i.p. over a 4-week period (Melief 
et al. 2011) and at a 10 mg/kg dose (McLaughlin et al. 2006; Bruchas et al. 2007a) with 
saline solution as a control. Housing cages contained only saline-treated or only norBNI-
treated mice.
(trans)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl] benzene-acetamide 
treatment
(trans)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cycloxhexyl] benzene-acetamide 
(U50,488H; Sigma Aldrich, Lyon, France) was administered subcutaneously (s.c.), as 
previously described (Simonin et al. 1998), at a 20 mg/kg dose.
Behavioral testing
Following repeated heroin injections, mice were maintained drug free in their home cages. 
Social behaviors were investigated 4 or 8 weeks later in a familiar environment (open-field 
arena), as previously described (Goeldner et al. 2011; Lutz et al. 2014).
Social interactions
Pairs of unfamiliar mice, from different home cages but of similar weight, were placed 
simultaneously for 10 minutes in the open-field arena, indirectly lit at 50 lux. Prior 
habituation to the arena and dim lighting both favor social interactions in poorly anxiogenic 
conditions (Goeldner et al. 2011). While in the present study, social interactions were 
measured using pairs of mice from the same treatment condition, our previous work (Lutz et 
al. 2014) suggests that similar effects of abstinence are observed when heroin-treated mice 
interact with naïve, opiate-free animals. Using an ethological keyboard, we measured the 
number of occurrences and the total duration of social interaction behaviors (sniffing, 
following and pawing contact), as well as of the individual grooming behavior.
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Tail immersion
The 52°C water is a commonly used nociceptive stimulus for opioid analgesia testing 
(Vaught & Takemori 1979; Mogil, Wilson & Wan 2001). Latency to withdraw the tail was 
measured by stopwatch. A cutoff time of 15 seconds was used to prevent heat-related tissue 
damage. For each mouse, pain-reflex latency was first measured at baseline. Then, 
U50,488H was administered with saline solution as a control, followed 30 minutes later 
(peak effect of the drug, refer to Bruchas et al. 2007b; Munro et al. 2012) by another 
measure of the pain reflex latency.
Statistical analyses
All data is expressed as mean ± SEM. Statistical analyses were performed using one- and 
two-way analyses of variance (ANOVA) with between-subjects (heroin abstinence, norBNI 
injections and FLX pellets) and within-subjects (U50,488H-induced analgesia) factors, in 
accordance with the experimental design. In case of significant interaction following 
ANOVA, multiple comparisons between groups were performed using Fischer’s post hoc. 
Statistical significance was defined as P < 0.05.
RESULTS
Low sociability during heroin abstinence can be both prevented and reversed by chronic 
antidepressant treatment with FLX
We showed previously that prolonged abstinence from chronic heroin exposure leads to the 
emergence of social withdrawal, a stable phenotype that can be detected at least from 4 to 7 
weeks following the end of heroin treatment (Lutz et al. 2014). Here, in a first set of 
experiments (n = 128 mice, refer to timeline in Fig. 1a), we examined the ability of chronic 
antidepressant treatment to prevent (FLX administered during weeks 2 to 5) or reverse (FLX 
administered during weeks 5 to 9) heroin abstinence-induced social deficit. For each 
prevention or reversion experiment (n = 64 mice), two animal cohorts (n = 32 mice/cohort; n 
= 16 mice/saline or heroin group in each cohort) were processed independently, and results 
were pooled. FLX-supplemented pellets were replaced by normal pellets 48 hours before 
behavioral testing to avoid acute effects of the drug. Results of the prevention experiments 
were consistent with our previous findings (Fig. 1b, left panels) (Lutz et al. 2014) and 
showed that heroin abstinence decreases social behaviors while potentiating self-grooming. 
We note also that no aggressive behaviors could be detected in heroin abstinent mice under 
our experimental conditions. Statistical analyses (two-way ANOVA) showed that social 
exploration time (sum of the durations of sniffing, pawing contact and following between 
pairs of mice of same treatment group) was affected by heroin pre-exposure [F(1,21) = 61.7, 
P < 0.0001] as well as by FLX treatment [F(1,21) = 30.6, P < 0.0001], with no significant 
interaction [F(1,21) = 2.11, P > 0.05]. Post hoc analyses showed a decrease in social 
interactions in heroin-control food mice, as compared with both saline-control food (P < 
0.0001), and heroin-FLX (P < 0.0001), mice. Heroin abstinence increased grooming 
[F(1,21) = 13.2, P < 0.005], a behavior that may represent an attempt to limit or avoid social 
contact (refer to our previous studies for a discussion). This effect was prevented by FLX [F 
(1,21) = 8.4, P < 0.05], with a significant interaction [F (1,21) = 7.4, P < 0.05]. Post hoc 
analysis showed that heroin-pretreated mice fed regular chow (heroin-control food) spent 
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more time grooming than saline controls (saline-control food, P < 0.001) or than heroin 
abstinent mice fed FLX pellets (P < 0.001). Therefore, a chronic antidepressant treatment 
targeting the serotonergic (5-HT) system is able to promote social interactions and limit 
aberrant grooming during long-term withdrawal, consistent with our previous observation of 
dynamic adaptations within 5-HT circuits during this time period (Goeldner et al. 2011; Lutz 
et al. 2011). We next wondered whether chronic FLX treatment might be beneficial in 
abstinent mice when administered at a later stage, after neurochemical adaptations have 
developed and low sociability has established (Fig. 1b, right panels). In these reversion 
experiments, two-way ANOVA analysis of social behaviors duration found significant 
detrimental and beneficial effects of heroin [F(1,25) = 6.7, P < 0.05] and FLX [F (1,25) = 
48.5, P < 0.0001], respectively, with a significant interaction [F(1,25) = 52.4, P < 0.0001]. 
Post hoc analyses showed a decrease in social interactions in heroin-control food mice, as 
compared with both saline-control food (P < 0.0001), and heroin-FLX (P < 0.0001), mice. 
Similar to results from prevention experiments, we also found that increased grooming 
induced by heroin pre-exposure [F (1,25) = 17.4, P < 0.0005] is reversed by FLX [F(1,25) = 
16.6, P < 0.0005], with a significant interaction [F (1,25) = 14.1, P < 0.005]. Post hoc 
analyses further confirmed that heroin-control food mice exhibit significantly longer 
grooming behaviors compared with both saline-control food (P < 0.0001), and heroin-FLX 
(P < 0.0001), mice. Altogether, the data show that a chronic FLX treatment is able to both 
prevent and reverse social withdrawal, which has developed during heroin abstinence.
Two norBNI injections are sufficient to significantly block KOR signaling during a 4-week 
period
The long-lasting KOR antagonist activity of norBNI was described originally by several 
groups of investigators to last in vivo around 14 to 21 days (in both rodents, Bruchas et al. 
2007b; Munro et al. 2012; Patkar et al. 2013, and rhesus monkeys, Butelman et al. 1993). 
While extremely long compared with most opiates, the reported duration of norBNI effects 
is shorter than the 4-week abstinence period in our model. We therefore determined the 
number of injections necessary to block KOR signaling during the entire 4-week abstinence 
period.
To this aim, we tested the analgesic effect of the KOR agonist U50,488H 4 weeks after a 
single i.p. norBNI injection (refer to timeline in Fig. 2a and results in Fig. 2b, left bottom 
panel). As expected, two-way ANOVA showed a significant analgesic effect of U50,488H, 
with an increase in the tail withdrawal latency [F(1,10) = 11.87, P < 0.01]. We noted, 
however, that norBNI had no statistically significant effect [F(1,10) = 1.99, P = 0.18], with 
no interaction between U50,488H and norBNI [F (1,10) = 1.9, P = 0.19], indicating that the 
later compound no longer significantly antagonized the KOR 4 weeks after a single 
injection. We then tested KOR-dependent antinociception following two norBNI injections 
separated by a 2-week interval (refer to timeline in Fig. 2a and results in Fig. 2b, right 
bottom panel). Results again confirmed the effect of U50,488H [F(1,9) = 11.74, P < 0.01]. 
Importantly, we also found a significant effect of norBNI [F(1,9) = 7.3, P < 0.05] with a 
tendency for an interaction [F(1,9) = 4.23, P = 0.06]. Post hoc analyses confirmed a 
significant analgesic effect of U50,488H in saline-treated controls (P < 0.005) but not in 
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norBNI-treated mice (P = 0.37). Accordingly, we decided to use a two-injection paradigm 
for later experiments in heroin abstinence mice.
In this experimental series, we also examined whether long-term blockade of endogenous 
KOR signaling might impact on the expression of social behaviors in naive mice. Social 
interactions were tested prior analgesic testing to limit stress effects of the pain assay. 
Results showed that in the single norBNI injection paradigm (Fig. 2b, left upper panel), 
norBNI had no significant effect on either social interactions (P = 0.32) or self-grooming (P 
= 0.82). Similarly, two injections of norBNI (Fig. 2b, right upper panel) had no effect on 
social (P = 0.11) or grooming (P = 0.10) behaviors. We conclude that, under basal 
conditions, sociability levels are not controlled by endogenous KOR signaling in adult mice, 
a finding that is consistent with our previous results in KOR knockout animals (Lutz et al. 
2014).
Low sociability during heroin abstinence is both prevented and reversed with two 
systemic injections with the KOR antagonist norBNI
We next examined whether the two-injection norBNI regimen, which is sufficient to block 
KOR signaling over a 4-week period, prevents the emergence of low sociability in heroin 
abstinent animals. Similar to our experiments using FLX (n = 128 mice, refer to timeline in 
Fig. 3a), we examined whether chronic blockade of the KOR would prevent or reverse 
abstinence-induced deficits.
In the prevention experiment (n = 64 mice), the two norBNI injections were performed 24 
hours and 2 weeks following the last heroin injection. Results revealed a significant effect of 
heroin abstinence [F(1.28) = 18.4, P < 0.001] and a significant interaction between 
abstinence and norBNI [F(1,28) = 16.1, P < 0.001], on the total duration of social behaviors 
(Fig. 3b, left upper panel). NorBNI had no main effect [F(1,28) = 2.8, P = 0.11]. Post hoc 
analyses confirmed that, in the absence of any norBNI exposure, social behaviors were 
decreased in heroin-pretreated compared with saline-pretreated abstinent animals (P < 
0.0001). Importantly, two norBNI injections were sufficient to restore sociability to normal 
values in heroin-pretreated groups (P < 0.001), a striking effect that matches the efficacy of 
chronic FLX. As for grooming (Fig. 3b, left bottom panel), we found significant effects of 
heroin [F(1,28) = 13.3, P < 0.005] and norBNI [F(1,28) = 6.5, P < 0.05], with an interaction 
[F(1.28) = 5.54, P < 0.05]. Post hoc analyses revealed that, in the absence of norBNI 
exposure, heroin pretreatment significantly increased grooming behaviors (P < 0.0005). This 
effect was completely reversed by KOR blockade, as shown when comparing norBNI- and 
saline-treated mice in the two heroin abstinent groups (P < 0.005). Altogether, these results 
clearly demonstrate that two norBNI injections are sufficient to completely block heroin 
abstinence effects on sociability, as well as on self-centered, grooming behaviors.
Next, we explored the efficacy of norBNI in reversing the effects of heroin. In these 
reversion experiments (n = 64 mice), the two norBNI injections were performed 4 and 6 
weeks following the last heroin injection, when impaired sociability is already prominent 
(Lutz et al. 2014). Results from the two-way ANOVA analysis showed that heroin 
abstinence [F(1,17) = 21.1, P < 0.0005] and norBNI [F(1,17) = 5.5, P < 0.05] had opposed 
and significant effects on social behaviors (Fig. 3b, right upper panel), with a strong 
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interaction between the two factors [F(1,17) = 13.1, P < 0.005]. Post hoc group comparisons 
confirmed that, in the absence of norBNI administration, sociability was strongly impaired 
following a 8-week abstinence period (P < 0.0001). In addition, comparing the two heroin-
pretreated groups showed that this deficit was potently reversed by norBNI (P < 0.0001). We 
also analyzed the duration of grooming (Fig. 3b, right bottom panel) and found effects of 
both heroin [F(1,17) = 20.9, P < 0.0005] and norBNI [F (1,17) = 29.7, P < 0.0001], as well 
as a significant interaction [F(1,17) = 21.6, P < 0.001]. Post hoc analyses further 
demonstrated that heroin abstinent mice show increased grooming compared with saline 
controls (P < 0.0001), an effect that was not observed following norBNI injections (P < 
0.0001). Altogether, our results indicate that norBNI can be administered in long-term 
abstinent mice to reverse heroin-induced social withdrawal.
Compared with our preliminary analyses in naive mice (refer to Fig. 2), here norBNI was 
administered to animals experiencing significantly higher levels of stress (with repeated i.p. 
injections), which may potentially modify (and likely potentiate, Bruchas et al. 2010; Knoll 
& Carlezon 2010; Lalanne et al. 2014) endogenous KOR activity. To confirm that the two-
injection norBNI regimen was still antagonizing KOR activity at the time of behavioral 
testing, U50,488H-induced antinociception was measured in both prevention and reversion 
experiments, following social interaction testing. Results showed that in prevention 
experiments (Fig. 3c, left panel), heroin pre-exposure had no effect [F(1,56) = 3.1, P = 0.09], 
suggesting that chronic MOR activation does not interfere with later KOR-mediated 
analgesia. In contrast, we found that norBNI [F(1,56) = 25.1, P < 0.0001] and U50,488H 
[F(2,56) = 109.0, P < 0.0001] had strong effects, with a significant interaction between these 
two treatments [F(1,56) = 25.6, P < 0.0001]. Post hoc group comparisons further indicated 
that U50,488H significantly increased tail withdrawal latency in saline-saline and heroin-
saline groups (P < 0.0005) but not in saline-norBNI or heroin-norBNI groups (P > 0.05). In 
the reversion experiments (Fig. 3c, right panel), U50,488H had a significant effect [F(1,46) = 
159.7, P < 0.0001], with a tendency for an effect of norBNI [F(1,46) = 3.5, P = 0.065], but 
not of heroin [F (1,46) = 2.8, P = 0.10]. We finally observed a strong interaction between 
U50,488H and norBNI [F(2,46) = 42.9, P < 0.0001], and post hoc comparisons found that 
U50,488H had significant effects in saline-saline (P < 0.005) and heroin-saline (P < 0.0005) 
groups but not in saline-norBNI or heroin-norBNI groups (P > 0.05). Overall, these results 
indicate that norBNI effectively blocked the KOR throughout abstinence.
DISCUSSION
Interactions with congeners represent major determinants of emotional well-being and 
resilience in both animal species and human. Disruption of social relationships is a hallmark 
of addiction (whatever the drug of abuse considered) and has been recognized as one of the 
diagnostic criteria most strongly associated with disease severity (Hasin et al. 2013). From a 
therapeutic perspective, medications that could help in restoring proper social functioning in 
addicted individuals are of great interest. Recently, we established an animal model of opiate 
abstinence in which impaired sociability (decreased interactions and increased grooming 
during a new social encounter) stands as a robust and long-lasting phenotype. While this 
model rely on experimentally delivered opiate injections and does not recapitulate important 
core dimensions of addiction (such as loss of control over drug seeking), our data indicate 
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that it has both face (strong physical dependence, low sociability and negative affective state 
during withdrawal) and predictive (beneficial effects of antidepressant medication) validities 
for the human condition (American Psychiatric Association 1994; Hyman, Malenka & 
Nestler 2006; George, Koob & Vendruscolo 2014). Here, building on this model, we further 
demonstrate that abstinence-induced social dysfunction is reversible and can be normalized 
by the 5-HT antidepressant FLX after it has established. Importantly, results from the 
present study further indicate that, in the same mouse model, two systemic injections with 
the KOR antagonist norBNI are sufficient to completely restore social behaviors to normal 
levels. Therefore, we propose that chronic blockade of the KOR may represent a powerful 
strategy for the management of social withdrawal in addicted individuals, alone or in 
combination with classical antidepressants.
Previous studies from our group (Goeldner et al. 2011) and others (Fadda et al. 2005; Tao & 
Auerbach 2005; Ferreira & Menescal-de-Oliveira 2012) indicate that chronic opiate 
exposure strongly activates the 5-HT system (an essential mediator of social behaviors), as 
revealed by increased 5-HT release and turnover across several brain regions, and also 
potently activates the hypothalamus–pituitary–adrenal stress axis. Our previous study 
showed that, with the exception of 5-HT levels in the dorsal raphe nucleus (DRN), all these 
effects attenuated with time while, in contrast, emotional deficits gradually developed along 
abstinence (Goeldner et al. 2011; Lutz et al. 2011). In particular, social avoidance 
strengthened to become significant after 4 weeks of drug withdrawal and persisted during at 
least three more weeks in the case of heroin (Lutz et al. 2011). Importantly, social 
withdrawal could not be attributed to changes in motor activity, anxiety-like behavior or 
hedonic tone (Lutz et al. 2014; Ayranci et al. 2015) and occurred before the emergence of 
despair-like behavior at 7 weeks of abstinence (Lutz et al. 2014), suggesting that deficient 
sociability precedes mood disruption during ongoing heroin abstinence. Further, we found 
that low sociability in abstinent mice was prevented when a chronic FLX treatment, known 
to potentiate 5-HT signaling, was initiated immediately after the last heroin injection. In the 
present study, we reproduced this finding and also examined whether delayed FLX 
administration, that is, after the 4-week abstinence period, would also be beneficial and 
reduce social behavior perturbations. Our results clearly indicate a complete reversion of the 
aberrant phenotype, with similar efficacy compared with prevention experiments, indicating 
that FLX has the capacity to restore normal functioning even after social avoidance has fully 
developed. Neurochemical and circuit mechanisms of FLX effects are unknown at this stage. 
For both prevention and reversion experiments, FLX could produce a true reversion of 
neuroadaptations that have developed either upon chronic opiate exposure (prevention 
experiment) or during abstinence (reversion experiment). Alternatively, FLX may trigger 
new adaptations that counteract the former modifications to restore normal behaviors. Future 
studies will be required to determine whether FLX-mediated restoration of social behaviors 
solely rely on the modulation of serotonergic neurons or recruit other neurotransmitters such 
as glutamatergic or noradrenergic signaling (the latter being tightly coupled with 5-HT 
neurons and known to be regulated by the KOR; Al-Hasani et al. 2013).
Because the KOR has prodepressant properties and has been recently suggested to inhibit 
social behaviors (Lutz & Kieffer 2013; Bilkei-Gorzo et al. 2014; Robles et al. 2014), we 
hypothesized that KOR signaling may play a role in the emergence of low sociability during 
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opiate abstinence. We recently obtained some evidence supporting this hypothesis, as 
knockout (KO) mice for the KOR developed a strikingly lower social withdrawal upon 
heroin abstinence, compared with controls (Lutz et al. 2014). In the later experiment, 
however, we noted that the intensity of physical dependence to heroin was also attenuated in 
the KOR mutant line, as shown in precipitated withdrawal experiments. Considering that 
physical withdrawal represents an aversive experience, it is possible that the milder 
withdrawal syndrome experienced by KOR KO mice during heroin exposure may contribute, 
at least partly, to the absence of social avoidance following abstinence in these mutants. In 
the present study, we used a pharmacological strategy to gain temporal control over KOR 
blockade. NorBNI was administered 24 hours after the end of intermittent heroin injections, 
thereby leaving unchanged the severity of physical withdrawal episodes that occurred after 
each heroin challenge. After establishing that two interspaced norBNI injections are 
sufficient to block KOR over 4-week duration (Fig. 2), we found that this two-injection 
regimen completely prevents the emergence of social impairment in abstinent mice. 
Therefore, we conclude that this phenotype does not result from the recruitment of KOR 
activities during repeated cycles of heroin intoxication and withdrawal but rather originates 
from KOR signaling during the abstinence period. Finally, we note that norBNI had no 
impact on sociability in control animals, indicating that this treatment specifically influenced 
long-term neuroadaptations that result from chronic heroin exposure and incubate during 
abstinence.
Similar to our reasoning with 5-HT signaling and FLX, we hypothesized that blockade of 
KOR activity could be beneficial both to prevent the development of social withdrawal 
during abstinence and also to reverse low sociability that has been established in abstinent 
animals. The KOR antagonist treatment was delayed and initiated after 4 weeks of 
abstinence, when the social phenotype is already constituted. Results indicate that norBNI 
injections fully reverse the heroin-induced phenotype with similar efficacy compared with 
the preventive norBNI intervention. These findings suggest that systemic norBNI 
administration may prove useful even in addicted subjects who already show signs of severe 
social isolation.
Results from these norBNI experiments strikingly mirror those obtained using FLX. A 
robust body of literature has recently demonstrated that KOR-dependent signaling pathways 
within DRN 5-HT neurons (such as the p38α kinase) mediate aversive responses in models 
of acute stress and stress-induced reinstatement of cocaine or nicotine drug seeking (Bruchas 
et al. 2007a; Land et al. 2009; Bruchas et al. 2011). Data also indicate that the nucleus 
accumbens (NAc) may be an important endpoint of KOR-dependent regulation of 5-HT 
neurons, which would ultimately affect dopaminergic signaling to produce behavioral effects 
(Bruchas et al. 2011; Schindler et al. 2012). Within this line, Zan et al. very recently 
provided interesting evidence in the specific context of opiate abstinence (Zan et al. 2015). 
Following chronic morphine exposure in mice, the authors showed that KOR blockade in the 
NAc could prevent abstinence-induced depressive-like behaviors and anhedonia (in the 
forced swim and sucrose preference tests, respectively). Together with our own results, the 
later findings therefore suggest that the NAc is critically located at the interplay of 5-HT and 
dopaminergic systems to control emotional homeostasis during opiate abstinence.
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Several rodent studies have explored the effects of chronic MOR activation on the 
expression and function of the KOR and its endogenous ligands, the dynorphins A and B 
peptides. Results suggest a complex pattern of responses, including different and even 
opposite changes in dynorphin levels depending on (i) the brain region, with an increase in 
the striatum and a decrease in the hippocampus and pituitary gland (Nylander, Vlaskovska & 
Terenius 1995a, 1995b); (ii) the timepoint, with an increase in the NAc after 4, but not 2 
weeks, of morphine withdrawal in mouse (Zan et al. 2015); and also (iii) genetic factors, 
with increased and decreased dynorphins in the VTA of Fischer and Lewis rats, respectively 
(Nylander et al. 1995a). A complete description of both dynorphin/KOR and 5-HT systems 
in the present heroin abstinence model, including FLX and norBNI treatment effects, will be 
instrumental to understand interactions between the two systems and design further 
molecular manipulations at targeted brain sites, including NAc as well as DRN or other 
brain sites involved in the social brain.
The present study is not without limitations, as heroin was delivered by the experimenter, 
during a relatively short period and at doses that likely do not produce acute reinforcing 
effects (Schlussman et al. 2008). Additional studies will be necessary to explore whether 
similar social dysfunction emerges following distinct drug exposure regimens (e.g. during 
longer periods, Williams et al. 2012, at doses that classically produce conditioned place 
preference, Schlussman et al. 2008, or in self-administration paradigms, Picetti et al. 2012) 
and its sensitivity to antidepressant or KOR antagonist medications. Beyond negative 
affective consequences of drug exposure, these additional paradigms have the potential to 
recapitulate other aspects of human addiction (such as loss of control over drug seeking).
In conclusion, previous studies focusing on rodent models of cocaine, nicotine, ethanol and 
opiate addictions consistently indicated that KOR antagonists may help prevent relapse 
episodes driven by stressful experiences or even drug-associated contexts (refer to Lalanne 
et al. 2014 for a recent review). Our study further expands the utility of KOR targeting 
compounds and suggests that they may also promote higher social functioning in addicted 
individuals. Importantly, two norBNI administrations only were sufficient to match the 
efficacy of a prolonged FLX administration. Therefore, the well-established long-acting 
properties of available KOR antagonists may help to improve compliance in opiate-
dependent patients, who typically prove difficult to retain over long-term follow-ups. Two 
clinical trials recently reported mixed results on the tolerability of two opiates with 
antagonist activity at the KOR (JDTic, Buda et al. 2015, buprenorphine, Karp et al. 2014), 
with evidence for a potential cardiac toxicity (Buda et al. 2015). Future studies will be 
necessary to characterize the risk/benefit balance of these compounds when used as 
antidepressants in clinical populations, notably in the context of opiate addiction.
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Figure 1. 
Chronic FLX treatment can both prevent and reverse low sociability in heroin abstinent 
mice. (a) Timeline for ‘Fluoxetine Prevention’ (upper panel) and ‘Fluoxetine Reversion’ 
(lower panel) experiments. Following heroin treatment, mice were maintained drug-free to 
experience spontaneous withdrawal for 4 weeks in prevention or 8 weeks in reversion 
experiments, followed by behavioral testing (Social Interactions). Mice were fed FLX-
supplemented pellets (10 mg/kg/24 hours) during weeks 2 to 5 or weeks 5 to 8, in prevention 
or reversion experiments, respectively. (b) Social Interactions in ‘Fluoxetine Prevention’ (left 
panel) and ‘Fluoxetine Reversion’ (right panel) experiments. Consistent with our previous 
findings, heroin abstinence reduced social behaviors and potentiated grooming. Both of 
these deficits were prevented (left panel) and reversed (right panel) by 4 weeks of per os 
FLX treatment. Data represented as mean ± SEM. #P < 0.05, ##P < 0.01, ###P < 0.001, 
ANOVA, main effect of heroin. +P < 0.05, +++P < 0.001, ANOVA main effect of FLX. 
***P < 0.001, post hoc FLX effect in heroin-FLX food mice as compared with heroin-
control food mice
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Figure 2. 
Two norBNI injections are sufficient to achieve chronic blockade of the kappa opioid 
receptor over 4 weeks. (a) Experimental time-line to assess chronic KOR blockade by one 
(upper panel) or two (lower panel) norBNI injections. Mice received one or two injections of 
norBNI (10 mg/kg, i.p.) over a 4-week time period. Four weeks after the first norBNI 
injection, mice underwent social interaction testing followed by U50,488H-induced 
analgesia (20 mg/kg, i.p.). (b) Social interactions (upper panels) and tail immersion (lower 
panels) in mice after one (left panels) or two (right panels) norBNI injections. Neither one 
nor two norBNI injections had significant effect on social behaviors and grooming. While 
the analgesic effect of U50,488H was still detectable 4 weeks after a single norBNI 
injection, two norBNI injections were able to prevent U50,488H-induced analgesia, in the 
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52°C tail immersion assay. Data represented as mean ± SEM. §§P < 0.01, ANOVA, main 
effect of U50,488H. ¥P < 0.01, ANOVA, main effect of norBNI. **P < 0.01, post hoc 
comparisons for the effect of U50,488H
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Figure 3. 
Chronic kappa opioid receptor norBNI antagonism prevents and reverses low sociability in 
heroin abstinent mice. (a) Timeline for ‘norBNI Prevention’ (upper panel) and ‘norBNI 
Reversion’ (lower panel) experiments. Following heroin treatment, mice experienced 
spontaneous withdrawal for 4 or 8 weeks, in prevention or reversion experiments, 
respectively. Two norBNI i.p. injections were used to achieve KOR blockade over a 4-week 
period. In ‘norBNI Prevention’ experiments, norBNI was administered 24 hours and 2 
weeks after the last heroin injection. In ‘norBNI Reversion’ experiments, injections were 4 
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and 6 weeks after heroin treatment. (b) Social Interactions in ‘norBNI Prevention’ (left 
panels) and ‘norBNI Reversion’ (right panels) experiments. In the absence of norBNI, 
heroin abstinence decreased social behaviors and increased grooming. Two norBNI 
injections were sufficient to prevent and reverse these deficits. (c) Tail immersion in ‘norBNI 
Prevention’ (left panel) and ‘norBNI Reversion’ (right panel) experiments. To confirm 
chronic KOR blockade, mice were tested for U50,488H-induced analgesia (20 mg/kg, i. p.) 
in the 52°C tail immersion test, after social interaction testing. norBNI significantly blocked 
U50,488H-induced analgesia in both heroin abstinent and control mice, in prevention as well 
as in reversion experiments. Data represented as mean ± SEM. #P < 0.05, ###P < 0.001, 
ANOVA, main effect of heroin; +P < 0.05, +++P < 0.001, ANOVA, main effect of norBNI; 
**P < 0.01, ***P < 0.001, post hoc norBNI effect in heroin-norBNI mice as compared with 
heroin-control mice; ¥P < 0.005, post hoc comparisons for the effect of U50,488H
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